Linagliptina Pharmapath

Linagliptin, the active ingredient in Linagliptina Pharmapath, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve glycaemic control when used as part of a comprehensive diabetes treatment plan.

GNH USA supplies Linagliptina Pharmapath as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and regulatory requirements to ensure product integrity across global markets.

Linagliptin is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus.

- Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose levels when used alone. - Type 2 diabetes mellitus (combination therapy): enhances glycaemic control when added to metformin or other oral antidiabetics. - Type 2 diabetes mellitus (post‑prandial control): reduces post‑prandial glucose excursions as part of a diet‑and‑exercise regimen.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nasal passages and throat. - Headache: transient head pain of varying intensity. - Upper respiratory tract infection: symptoms such as cough, sore throat, or congestion. - Dizziness: brief episodes of light‑headedness. - Gastrointestinal discomfort: mild nausea or abdominal pain. - Back pain: occasional musculoskeletal discomfort.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with possible vomiting, requiring immediate medical attention. - Severe allergic reactions: rash, swelling, or difficulty breathing. - Hepatic injury: elevated liver enzymes or jaundice. - Hypersensitivity reactions: including angioedema. - Severe joint pain: unexplained arthralgia. - Bullous skin reactions: blistering skin conditions.

Linagliptina Pharmapath should be used with clinical judgment and patient monitoring. - Renal impairment: assess renal function; dose adjustment may be required. - Hepatic impairment: monitor liver enzymes during therapy. - Cardiovascular disease: use with caution in patients with existing heart conditions. - Elderly patients: observe for signs of hypoglycaemia when combined with insulin or sulfonylureas. - Drug interactions: review all concomitant medications for potential interactions. - Store at room temperature: keep in the original packaging, protect from moisture and light.

Linagliptina Pharmapath may interact with other medicines; monitoring is advised.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase linagliptin exposure and risk of adverse effects. - Insulin or sulfonylureas: combined use can raise the risk of hypoglycaemia.

Moderate Interactions (Monitor Closely): - Rifampin: may reduce linagliptin effectiveness. - Diuretics: may influence glucose control. - ACE inhibitors: monitor renal function and blood pressure.